Weight Watchers (WW) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
The 2026 Annual Meeting will be held virtually on June 12, 2026, with shareholders able to vote and submit questions electronically.
Only shareholders of record as of April 20, 2026, are entitled to vote, with 9,998,760 shares outstanding.
The company emerged from Chapter 11 bankruptcy on June 24, 2025, with a new capital structure and board composition.
Voting matters and shareholder proposals
Shareholders will vote on the election of six directors, ratification of PricewaterhouseCoopers LLP as auditor, and an advisory say-on-pay vote for executive compensation.
The board recommends voting FOR all proposals.
Procedures for submitting shareholder proposals for the 2027 meeting are outlined, with deadlines and requirements specified.
Board of directors and corporate governance
The board consists of six independent directors, all elected annually, with a separation of CEO and Chairman roles.
Four standing committees: Audit, Compensation, Nominating and Corporate Governance (NCG), and Strategy and Finance (SF).
Board and committee charters, governance guidelines, and codes of conduct are available online.
The NCG Committee oversees sustainability and corporate responsibility plans.
Latest events from Weight Watchers
- Clinical growth and strong margins offset net loss; 2026 guidance and debt reduction reaffirmed.WW
Q1 20267 May 2026 - Clinical subscriber growth and higher ARPU drive 2026 outlook despite behavioral headwinds.WW
Q4 20251 May 2026 - Q2 2024 revenue fell 10.9% as clinical subscribers surged 120% and cost savings were targeted.WW
Q2 20242 Feb 2026 - Q3 revenue and subscribers fell, but clinical growth and cost actions supported margin gains.WW
Q3 202416 Jan 2026 - GLP-1 integration, financial restructuring, and targeted programs drive innovation and growth.WW
CJS Securities 26th Annual "New Ideas for the New Year” Investor Conference14 Jan 2026 - Clinical growth and cost cuts offset declines, but bankruptcy and high debt loom.WW
Q1 202514 Jan 2026 - Annual meeting to vote on directors, auditor, and executive pay, with strong governance and ESG focus.WW
Proxy Filing1 Dec 2025 - Q4 profit returned as clinical growth and cost actions offset revenue and subscriber declines.WW
Q4 20241 Dec 2025 - Debt cut by $1.15B, leverage below 3x, and operations continue during reorganization.WW
Investor Update25 Nov 2025